Abstract
The objective of this study was to investigate the radiobiological effects of Flattening Filter (FF) and Flattening Filter Free (FFF) beams on Malignant Melanoma cancer (MMe Ca) modeled NOD-Prkdc IL2rg tm1 (NSG) mice in vivo, with a specific focus on necrotic and immunofluorescent changes.Thirty-five adult NSG mice models were randomly divided into four groups; MMe Ca, FF with a low dose rate of 400 MU/min (FF-400) and FFF with a high dose rate of 1400 MU/min (FFF-1400), and Control. The NSG mice in FF-400 and FFF-1400 groups (MMe Ca plus RT groups) were irradiated with a single dose of 20 Gy at 400 MU/min and 1400 MU/min. Radiotherapy was administered to NSG mice 20 days after tumor transplantation. The mice were then sacrificed 2 days after radiotherapy for assessment of the necrotic area, cell proliferation and apoptosis.The Ki-67 proliferation index showed a significant increase (p < 0.05) in the MMe Ca group (G1) compared to the FF-400 and FFF-1400 radiotherapy groups (G2 and G3) and the control group (G4), whereas a significant decrease was observed in the radiotherapy groups due to single-dose 20Gy irradiation (p < 0.05). The apoptotic index increased with irradiation in the FF-400 and FFF-1400 radiotherapy groups (p < 0.05). The necrotic area values of FF-400 and FFF-1400 at different dose rates (G2 and G3) increased statistically significantly (p < 0.05) compared to the MMe Ca group (G1). In addition, the Ki-67 cell proliferation, apoptotic index, and necrotic area parameters exhibited statistically significant differences between the FF-400 and FFF-1400 beams (p < 0.05). The FFF-high dose rate beams were found to be more effective on MMe Ca compared to the FF conventional beams (p < 0.05).It was concluded that FF and FFF beams caused significant radiobiological changes in cell proliferation (Ki-67), apoptosis (TUNEL) and necrosis histopathological parameters and the FFF beam was more effective on MMe Ca.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.